Publication date: Jul 01, 2024
We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1. 5-adapted vaccine. Results suggest that XBB1. 5-adapted vaccines may have reduced effectiveness against JN. 1 versus XBB sublineages.
Open Access PDF
| Concepts | Keywords |
|---|---|
| California | BNT162b2 |
| February | COVID-19 |
| Reduced | JN.1 |
| Vaccine | vaccine effectiveness |
| XBB |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | effectiveness |
| disease | VO | vaccine |
| disease | VO | USA |
| disease | MESH | Infectious Diseases |
| disease | MESH | COVID 19 |
| disease | VO | vaccine effectiveness |
| drug | DRUGBANK | Methylphenidate |
| disease | MESH | severe acute respiratory syndrome |
| disease | VO | effective |
| disease | VO | vaccination |
| disease | MESH | infection |
| disease | MESH | emergency |
| disease | VO | vaccinated |
| drug | DRUGBANK | Methionine |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | organization |
| disease | VO | vaccine strain |
| disease | VO | report |
| disease | VO | publication |
| drug | DRUGBANK | Guanosine |
| disease | IDO | host |
| disease | IDO | blood |
Original Article
(Visited 3 times, 1 visits today)